Clinical Publications 2022
 
  1. Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. ITAC (INSIGHT 013) Study Group.
    Lancet. 2022:S0140-6736(22)00101-5. Abstract
     
  2. Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting. Greenberg L, Ryom L, Neesgaard B, Miró JM, Dahlerup Rasmussen L, Zangerle R, Grabmeier-Pfistershammer K, Günthard HF, Kusejko K, Smith C, Mussini C, Menozzi M, Wit F, Van Der Valk M, d'Arminio Monforte A, De Wit S, Necsoi C, Pelchen-Matthews A, Lundgren J, Peters L, Castagna A, Muccini C, Vehreschild JJ, Pradier C, Bruguera Riera A, Sönnerborg A, Petoumenos K, Garges H, Rogatto F, Dedes N, Bansi-Matharu L, Mocroft A; RESPOND Study Group.
    Open Forum Infect Dis. 2022;9(3):ofac029. Abstract
     
  3. Achromobacter spp. in a Cohort of Non-Selected Pre- and Post-Lung Transplant Recipients. Crone CG, Rezahosseini O, Schultz HHL, Qvist T, Johansen HK, Nielsen SD, Perch M.
    Pathogens. 2022;11(2):181. Abstract
     
  4. Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis. Andreasen PB, Rezahosseini O, Møller DL, Wareham NE, Thomsen MT, Houmami R, Knudsen AD, Knudsen J, Kurtzhals JAL, Rostved AA, Pedersen CR, Rasmussen A, Nielsen SD.
    Immun Inflamm Dis. 2022;10(1):93-100. Abstract
     
  5. Integrative Lipidomics and Metabolomics for System-Level Understanding of the Metabolic Syndrome in Long-Term Treated HIV-Infected Individuals. Olund Villumsen S, Benfeitas R, Knudsen AD, Gelpi M, Høgh J, Thomsen MT, Murray D, Ullum H, Neogi U, Nielsen SD.
    Front Immunol. 2022;12:742736. Abstract
     
  6. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. Byonanebye DM, Polizzotto MN, Neesgaard B, Sarcletti M, Matulionyte R, Braun DL, Castagna A, de Wit S, Wit F, Fontas E, Vehreschild JJ, Vesterbacka J, Greenberg L, Hatleberg C, Garges H, Gallant J, Volny Anne A, Öllinger A, Mozer-Lisewska I, Surial B, Spagnuolo V, Necsoi C, van der Valk M, Mocroft A, Law M, Ryom L, Petoumenos K; RESPOND study group.
    HIV Med. 2022. Epub ahead of print. Abstract
     
  7. Posttransplantation Diabetes Mellitus Among Solid Organ Recipients in a Danish Cohort. Dos Santos Q, Hornum M, Terrones-Campos C, Crone CG, Wareham NE, Soeborg A, Rasmussen A, Gustafsson F, Perch M, Soerensen SS, Lundgren J, Feldt-Rasmussen B, Reekie J.
    Transpl Int. 2022;35:10352. Abstract
     
  8. Risk of Bacterial, Viral, and Fungal Infections in Patients With Solid Malignant Tumors Treated With Curative Intent Radiation Therapy. Terrones-Campos C, Ledergerber B, Specht L, Vogelius IR, Helleberg M, Lundgren J.
    Adv Radiat Oncol. 2022;7(6):100950. Abstract
     
  9. Patients with CLL have lower risk of death from COVID-19 in the omicron era. Niemann CU, da Cunha-Bang C, Helleberg M, Ostrowski SR, Brieghel C.
    Blood. 2022:blood.2022016147. Abstract
     
  10. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium Neesgaard B, Greenberg L, Miró JM, Grabmeier-Pfistershammer K, Wandeler G, Smith C, De Wit S, Wit F, Pelchen-Matthews A, Mussini C, Castagna A, Pradier C, d'Arminio Monforte A, Vehreschild JJ, Sönnerborg A, Anne AV, Carr A, Bansi-Matharu L, Lundgren JD, Garges H, Rogatto F, Zangerle R, Günthard HF, Rasmussen LD, Necsoi C, van der Valk M, Menozzi M, Muccini C, Peters L, Mocroft A, Ryom L.
    Lancet HIV. 2022:S2352-3018(22)00094-7. Abstract
     
  11. The gut microbiome in patients with chronic lymphocytic leukemia. Faitová T, Svanberg R, Da Cunha-Bang C, Ilett EE, Jørgensen M, Noguera-Julian M, Paredes R, MacPherson CR, Niemann CU.
    Haematologica. 2022. Epub ahead of print. Abstract
     
  12. Increased incidence rates of positive blood cultures shortly after chemotherapy compared to radiotherapy among individuals treated for solid malignant tumours. Roen A, Terrones C, Bannister W, Helleberg M, Andersen MA, Niemann CU, Daugaard G, Specht L, Mocroft A, Reekie J, Lundgren J.
    Infection. 2022. Epub ahead of print. Abstract
     
  13. Development and Validation of a Risk Score for Post-Transplant Lymphoproliferative Disorders among Solid Organ Transplant Recipients. Dos Santos Q, Wareham NE, Mocroft A, Rasmussen A, Gustafsson F, Perch M, Sørensen SS, Manuel O, Müller NJ, Lundgren J, Reekie J.
    Cancers (Basel). 2022;14(13):3279. Abstract
     
  14. Early- and late-onset posttransplant lymphoproliferative disorders among adult kidney and liver transplant recipients. Abdulovski R, Møller DL, Knudsen AD, Sørensen SS, Rasmussen A, Nielsen SD, Wareham NE.
    Eur J Haematol. 2022. Epub ahead of print. Abstract
     
  15. Validation of cause of death classification after heart transplantation and cause-specific life expectancy compared to the general population. Gjesdal G, Lundgren J, Czuba T, Wareham NE, Gustafsson F, Nilsson J, Smith JG, Braun OÖ.
    Clin Transplant. 2022:e14756. Epub ahead of print. Abstract
     
  16. Trends in underlying causes of death in solid organ transplant recipients between 2010 and 2020: Using the CLASS method for determining specific causes of death. Søborg A, Reekie J, Rasmussen A, Cunha-Bang CD, Gustafsson F, Rossing K, Perch M, Krohn PS, Sørensen SS, Lund TK, Sørensen VR, Ekenberg C, Lundgren L, Lodding IP, Moestrup KS, Lundgren J, Wareham NE.
    PLoS One. 2022;17(7):e0263210. Abstract
     
  17. Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study.  Søgaard OS, Reekie J, Johansen IS, Nielsen H, Benfield T, Wiese L, Stærke NB, Iversen K, Fogh K, Bodilsen J, Iversen M, Knudsen LS, Klastrup V, Larsen FD, Andersen SD, Hvidt AK, Andreasen SR, Madsen LW, Lindvig SO, Øvrehus A, Ostrowski SR, Abildgaard C, Matthews C, Jensen TO, Raben D, Erikstrup C, Fischer TK, Tolstrup M, Østergaard L, Lundgren J; ENFORCE Writing Group.
    Clin Microbiol Infect. 2022;28(8):1126-1133 Abstract
     
  18. Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections. Stærke NB, Reekie J, Nielsen H, Benfield T, Wiese L, Knudsen LS, Iversen MB, Iversen K, Fogh K, Bodilsen J, Juhl MR, Lindvig SO, Øvrehus A, Madsen LW, Klastrup V, Andersen SD, Juhl AK, Andreasen SR, Ostrowski SR, Erikstrup C, Fischer TK, Tolstrup M, Østergaard L, Johansen IS, Lundgren J, Søgaard OS.
    Nat Commun. 2022;13(1):4466. Abstract
     
  19. Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group.
    Lancet Respir Med. 2022:S2213-2600(22)00215-6. Abstract
     
  20. Observational cohort study of rilpivirine (RPV) utilization in Europe. Cozzi-Lepri A, Peters L, Pelchen-Matthews A, Neesgaard B, De Wit S, Johansen IS, Edwards S, Stephan C, Adamis G, Staub T, Zagalo A, Domingo P, Elbirt D, Kusejko K, Brännström J, Paduta D, Trofimova T, Szlavik J, Zilmer K, Losso M, Van Eygen V, Pai H, Lundgren J, Mocroft A; EuroSIDA Study Group.
    AIDS Res Ther. 2022;19(1):38. Abstract
     
  21. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial. ACTIV-3/TICO Study Group.
    Ann Intern Med. 2022. Epub ahead of print. Abstract
     
  22. Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial. ACTIV-3/TICO Bamlanivimab Study Group, Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, Files DC, Jain MK, Benfield T, Bowdish ME, Leshnower BG, Baker JV, Jensen JU, Gardner EM, Ginde AA, Harris ES, Johansen IS, Markowitz N, Matthay MA, Østergaard L, Chang CC, Goodman AL, Chang W, Dewar RL, Gerry NP, Higgs ES, Highbarger H, Murray DD, Murray TA, Natarajan V, Paredes R, Parmar MKB, Phillips AN, Reilly C, Rupert AW, Sharma S, Shaw-Saliba K, Sherman BT, Teitelbaum M, Wentworth D, Cao H, Klekotka P, Babiker AG, Davey VJ, Gelijns AC, Kan VL, Polizzotto MN, Thompson BT, Lane HC, Neaton JD.
    Ann Intern Med. 2022;175(2):234-243. Abstract
     
  23. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group.
    Lancet Infect Dis. 2022;22(5):622-635. Abstract
     
  24. Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery. Douin DJ, Siegel L, Grandits G, Phillips A, Aggarwal NR, Baker J, Brown SM, Chang CC, Goodman AL, Grund B, Higgs ES, Hough CL, Murray DD, Paredes R, Parmar M, Pett S, Polizzotto MN, Sandkovsky U, Self WH, Young BE, Babiker AG, Davey VJ, Kan V, Gelijns AC, Matthews G, Thompson BT, Lane HC, Neaton JD, Lundgren JD, Ginde AA; ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group.
    Am J Respir Crit Care Med. 20227. Epub ahead of print. Abstract
     
  25. RAGE has potential pathogenetic and prognostic value in nonintubated hospitalized patients with COVID-19. Wick KD, Siegel L, Neaton JD, Oldmixon C, Lundgren J, Dewar RL, Lane HC, Thompson BT, Matthay MA; ACTIV-3/TICO study group.
    JCI Insight. 2022;7(9):e157499. Abstract
     
  26. Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA study. Nikolaichuk M, Mocroft A, Wandeler G, Szlavik J, Gottfredsson M, Reikvam DH, Svedhem V, Elinav H, Laguno M, Mansinho K, Devitt E, Chkhartishvili N, Behrens G, Bogner J, Viard JP, Winston A, Benfield T, Leen C, Fursa O, Rockstroh J, Peters L; EuroSIDA study group.
    HIV Med. 2022. Epub ahead of print. Abstract
     
  27. Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens. Bannister WP, Mast TC, de Wit S, Gerstoft J, Wiese L, Milinkovic A, Hadziosmanovic V, Clarke A, Rasmussen LD, Lacombe K, Schommers P, Staub T, Zagalo A, Portu JJ, Tau L, Calmy A, Cavassini M, Gisinger M, Borodulina E, Mocroft A, Reekie J, Peters L; EuroSIDA study group.
    AIDS. 2022. Epub ahead of print. Abstract
     
  28. Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO). Mylonakis E, Lutaakome J, Jain MK, Rogers AJ, Moltó J, Benet S, Mourad A, Files DC, Mugerwa H, Kityo C, Kiweewa F, Nalubega MG, Kitonsa J, Nabenkema E, Murray DD, Braun D, Kamel D, Higgs ES, Hatlen TJ, Kan VL, Sanchez A, Tierney J, Denner E, Wentworth D, Babiker AG, Davey VJ, Gelijns AC, Matthews GV, Thompson BT, Lane HC, Neaton JD, Lundgren JD.
    Med (N Y). 2022;3(8):531-537. Abstract
     
  29. Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning. Zucco AG, Agius R, Svanberg R, Moestrup KS, Marandi RZ, MacPherson CR, Lundgren J, Ostrowski SR, Niemann CU.
    Sci Rep. 2022;12(1):13879. Abstract
     
  30. Readmissions, post-discharge mortality and sustained recovery among patients admitted to hospital with COVID-19.  Moestrup KS, Reekie J, Zucco AG, Jensen TØ, Jensen JUS, Wiese L, Ostrowski SR, Niemann CU, MacPherson C, Lundgren J, Helleberg M.
    Clin Infect Dis. 2022:ciac639. Epub ahead of print. Abstract
     
  31. The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19. ACTIV-3/TICO Study Group.
    Ann Intern Med. 2022. Epub ahead of print. Epub ahead of print. Abstract
     
  32. Low spontaneous clearance rates of recently acquired hepatitis C virus in HIV-positive MSM (The PROBE-C Study). Monin MB, Ingiliz P, Lutz T, Scholten S, Cordes C, Martínez-Rebollar M, Spinner CD, Nelson M, Rausch M, Bhagani S, Peters L, Reiberger T, Mauss S, Rockstroh JK, Boesecke C; PROBE-C study group.
    Clin Infect Dis. 2022:ciac680. Abstract
     
  33. Uptake of the lateral flow urine LAM test in Europe and Central Asia. Kraef C, Yedilbayev A, Seguy N, Bentzon A, Podlekareva D, Cirillo DM, van der Werf MJ, Kirk O.
    Int J Tuberc Lung Dis. 2022;26(9):835-841. Abstract
     
  34. Diagnostic toolkit for tuberculosis: should we include urine lipoarabinomannan (LAM) detection in the WHO European Region? Kraef C, Lindquist E, Svensson E, Cambau E.
    Clin Microbiol Infect. 2022:S1198-743X(22)00336-6. Abstract
     
  35. Monitoring progress towards elimination of hepatitis B and C in the EU/EEA. Sharrock KC, Noori T, Axelsson M, Buti M, Diaz A, Fursa O, Hendrickx G, James J, Klavs I, Korenjak M, Maticic M, Mozalevskis A, Peters L, Rigoni R, Rosinska M, Ruutel K, Eberhard Schatz, Thomas Seyler, Irene Veldhuijzen, Duffell E.
    PLOS Glob Public Health. 2022; 2(8): e0000841. Abstract
     
  36. Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV. Jaschinski N, Greenberg L, Neesgaard B, Miró JM, Grabmeier-Pfistershammer K, Wandeler G, Smith C, De Wit S, Wit F, Pelchen-Matthews A, Mussini C, Castagna A, Pradier C, Monforte A, Vehreschild J, Sönnerborg A, Anne AV, Carr A, Bansi-Matharu L, Lundgren J, Garges H, Rogatto F, Zangerle R, Günthard HF, Rasmussen LD, Nescoi C, Van Der Valk M, Menozzi M, Muccini C, Mocroft A, Peters L, Ryom L; RESPOND Study Group.
    AIDS. 2022. Epub ahead of print.Abstract
     
  37. Post-Transplantation Anemia and Risk of Death Following Lung Transplantation. Bugge TB, Perch M, Rezahosseini O, Crone CG, Jensen K, Schultz HH, Bredahl P, Hornum M, Nielsen SD, Lund TK.
    Transplant Proc. 2022:S0041-1345(22)00508-5. Abstract
     
  38. Added Value of Reanalysis of Whole Exome- and Whole Genome Sequencing Data From Patients Suspected of Primary Immune Deficiency Using an Extended Gene Panel and Structural Variation Calling. Mørup SB, Nazaryan-Petersen L, Gabrielaite M, Reekie J, Marquart HV, Hartling HJ, Marvig RL, Katzenstein TL, Masmas TN, Lundgren J, Murray DD, Helleberg M, Borgwardt L.
    Front Immunol. 2022;13:906328. Abstract
     

IN PRESS

  1. Incidence and risk factors for suicide, death due to substance use, and violent/accidental death in persons living with HIV. Erich S. Tusch, Lene Ryom, Olga Fursa, Lars Peters, Lars Oestergaard, Eric Florence, Simon Edwards, Christian Hoffmann, Helen Sambatakou, Peter Reiss, Eduardo Shahar, Dag Henrik Reikvam, Brigitte Schmied, Dzmitry Paduta, Alexei Yakovlev, János Szlávik, Jovan Ranin, Kai Zilmer, Vilma Uždaviniene, Annegret Pelchen-Matthews, Amanda Mocroft, Joanne Reekie for the EuroSIDA Study Group.
    AIDS. 2022
     
  2. The role of HIV/HBV/HCVRNA+ triple infection in end-stage liver disease and all-cause mortality in Europe. Amanda MOCROFT for the EuroSIDA study group.
    AIDS, 2022
     
  3. Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines. Astrid K Hvidt, Eva A M Baerends, Ole S Søgaard, Nina B Stærke, Dorthe Raben, Joanne Reekie, Henrik Nielsen, Isik Somuncu Johansen, Lothar Wiese, Thomas L Benfield, Kasper K Iversen, Ahmed B Mustafa, Maria R Juhl, Kristine T Petersen, Sisse Rye Ostrowski, Marianne H Schleimann, Sidsel D Andersen, Anna K Juhl, Lisa L Dietz, Signe R Andreasen, Jens Lundgren, Lars Jørgen Østergaard, Martin Tolstrup
    Frontiers in Medicine, 2022
     
  4. Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection Begré Lorin, Béguelin Charles, Boyd Anders, Peters Lars, Rockstroh Jürgen, Günthard Huldrych F., Bernasconi Enos, Cavassini Matthias, Lacombe Karine, Mocroft Amanda, Wandeler Gilles, Rauch Andri.
    Frontiers in Medicine, 2022
     
  5. Low risk of failing direct-acting antivirals in people with HIV/HCV from Sub-Saharan Africa or Southeastern Asia: a European cross-sectional study. Cas Isfordink, Anders Boyd, Amanda Mocroft, Katharina Kusejko, Colette Smit, Stephane de Wit, Tabitha Mahungu, Karolin Falconer, Gilles Wandeler, Matthias Cavassini, Marcel Stöckle, Janke Schinkel, Andri Rauch, Lars Peters, Marc van der Valk, on behalf of EuroSIDA, the Swiss HIV Cohort Study and the ATHENA observational cohort Open Forum Infectious Diseases, 2022